Retatrutide, a novel dual agonist of the GLP-1 binding site and glucose-dependent secreted polypeptide (GIP) binding site , is showing promising results in initial patient studies. Recent research https://atozbookmarkc.com/story21579748/retatrutide-emerging-research-and-projected-medical-uses